Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. - Wikidata - wikimedia - TriplyDB

Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.

Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.

http://www.wikidata.org/entity/Q36602177

about

Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy The emerging role of FTY720 (Fingolimod) in cancer treatment Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia Cancer therapy in the necroptosis era Inhibition of acid sphingomyelinase by tricyclic antidepressants and analogons The mechanism of necroptosis in normal and cancer cells Regulation of PP2A by Sphingolipid Metabolism and Signaling The Basic Biology of PP2A in Hematologic Cells and Malignancies PP2A: The Wolf in Sheep's Clothing?Ceramide induced mitophagy and tumor suppression FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels Key roles of necroptotic factors in promoting tumor growth FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.Sphingosine 1-phosphate receptor-1 enhances mitochondrial function and reduces cisplatin-induced tubule injury.Emerging roles for lipids in non-apoptotic cell death The differential effects of FTY720 on functional recovery and infarct size following myocardial ischaemia/reperfusion.Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget.Loss of neutral ceramidase protects cells from nutrient- and energy -deprivation-induced cell death.Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies Advances in the management of peritoneal mesothelioma Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry.Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond.PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.Shikonin kills glioma cells through necroptosis mediated by RIP-1 Ciliary transport regulates PDGF-AA/αα signaling via elevated mammalian target of rapamycin signaling and diminished PP2A activity.Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia Sphingolipid metabolites in inflammatory disease.Retinoic acid modulates interferon-γ production by hepatic natural killer T cells via phosphatase 2A and the extracellular signal-regulated kinase pathway Cardamonin Suppresses TGF-β1-Induced Epithelial Mesenchymal Transition via Restoring Protein Phosphatase 2A Expression PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects Cellular and molecular interactions of phosphoinositides and peripheral proteins Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation.Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia.A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia.Destabilisation of dimeric 14-3-3 proteins as a novel approach to anti-cancer therapeutics.Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.Ceramide-Initiated Protein Phosphatase 2A Activation Contributes to Arterial Dysfunction In Vivo.Differential regulation of autophagy and cell viability by ceramide species.

P2860

Q26739959-69351C1B-13B3-4A8C-AB6D-D12B18635EC1 Q26748927-9ED07A26-BC1C-49EE-BD32-6CF20323A34D Q26752430-D53EB497-EFAC-49D4-BD21-FAC7F50CEDFC Q26766339-171315FF-E68D-4338-BCF2-C96CB1F91A25 Q26852322-28D1B182-3ADF-499C-938E-7CE41DD2267A Q27005878-11BD1A0D-3E8C-4F3F-92AE-04D548A3A630 Q27026038-1C761103-D81B-4F88-866B-BABA7B94D67F Q28088697-473E58DF-5FE7-474C-98FC-3B4369A64B49 Q28088747-6FDD36B8-238B-4D3B-BEE0-8907D93FB8E9 Q28384389-8CB76B37-6FDE-4568-AAC8-E4D6FB2D9691 Q28541065-219F6A44-5A1A-4514-82D4-35C64B0FDF22 Q28828140-18606399-44C4-43CF-AD16-42B434051BCC Q29248124-103799BE-A747-437A-BA60-9DB71538E5A4 Q30252408-44554F1B-A9A7-4422-8A93-EDC5908BAF28 Q30359883-F99A6652-BF1A-4CAE-B205-8C41DEC798D0 Q33586741-BB95915E-A4CD-4FD3-964E-D8149157BEA9 Q33613072-7EEEBFA8-13EC-4B4C-B6CE-DBB139B5D4F4 Q33829692-3D45A8F9-B9DE-4417-9109-08E1FFD59BBB Q33909832-1AFB7A1B-C8C0-4DA7-A4D1-92D4878503F5 Q33977247-3FEF80C4-542B-4EFB-80F9-BCAB2991EFAB Q34043449-B70C1958-F33C-451A-A1B2-BD7FE01C00F9 Q34137322-1B612E41-FE0C-4D5A-B37C-6FAA49B3DB1E Q34266856-A6954AA2-1985-4FFA-AB9A-0E68BEDC4306 Q34364844-4B53802C-E054-4F22-B0AF-77AFAE440E2A Q34504365-7E742AB5-4087-4875-96AC-0273F18CA117 Q34805282-792E29DA-BC9C-46AE-B95C-4F506D213B5D Q34960781-5E9926E6-68D4-424E-BF84-23DD86EC87EE Q35037262-FAC297BF-0E91-4CE8-93B6-7184D297DF1A Q35061720-1F5BE0B9-C9FF-402F-9739-FBE821E870CD Q35148930-EB167F9F-8862-4BD5-B569-DEAB1525135A Q35161277-09A2A9E2-0697-4D06-A1BF-6058E0CB78E9 Q35552005-EFC51819-1A4C-478D-82A6-16B9CF57416E Q35794843-AC24B01D-53EC-4721-8181-1F3CCAA32A95 Q35820032-5F6E1E18-C01E-4783-B5CB-E9F85E2D8ECE Q35828517-9ACF5689-233B-4CC5-94B8-3BB5571F121F Q35953902-1FE250BB-78E2-4EF7-B0DA-E76FEC19B3D4 Q35987404-D422C642-4631-4173-91F0-EE67E66BC655 Q36020877-5C674C18-DE51-41BD-B6EB-67016DDC617D Q36186252-5C87DD21-D61C-48D3-B030-816CDE64B74D Q36214943-6A55F8E3-74C2-4B11-9412-78DB705EA1CD

P2860

Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.

http://www.wikidata.org/entity/Q36602177

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Sphingosine analogue drug FTY7 ...... A-RIPK1-dependent necroptosis.

@ast

Sphingosine analogue drug FTY7 ...... A-RIPK1-dependent necroptosis.

@en

type

label

Sphingosine analogue drug FTY7 ...... A-RIPK1-dependent necroptosis.

@ast

Sphingosine analogue drug FTY7 ...... A-RIPK1-dependent necroptosis.

@en

prefLabel

Sphingosine analogue drug FTY7 ...... A-RIPK1-dependent necroptosis.

@ast

Sphingosine analogue drug FTY7 ...... A-RIPK1-dependent necroptosis.

@en

P1433

Q36602177-1275F9C2-AE81-4897-8621-55593207354E

P1476

Q36602177-9EBDFB2E-B071-4D5E-8C06-ED0C5792C608

P2093

Q36602177-0A74433B-DB0B-44ED-81F5-9D044D3033A1

Q36602177-109B0F6D-75CA-4536-B8D4-E661D179619C

Q36602177-142DC562-2950-4121-ABF9-84C0574783BB

Q36602177-2063C82A-3181-4EB7-AAC2-28A18D072583

Q36602177-23C2C6E8-E3AC-4AE2-82EC-F18E63AA138F

Q36602177-60E91C6F-EAC2-41CC-B6DE-1FF890BC16B8

Q36602177-637D12AC-A3E9-4635-9252-BA6319D4B8C6

Q36602177-667D43AC-FCCF-419D-BD81-7E840DCF7061

Q36602177-669D0EE6-BCCB-4782-A871-F8144D2FC927

Q36602177-765870D1-E7CF-41D9-B9DC-DE480CC2C464

P2860

Q36602177-132089CE-D995-44D3-9EAF-180D00357B31

Q36602177-1B117AD8-2F41-4869-B24C-471DDFF01624

Q36602177-1C958D11-4D2C-4916-A9D4-44A5F37E9771

Q36602177-1CAF4BF8-CA85-49D3-8365-B90C3EAFF2DD

Q36602177-20C380E3-9119-435D-81DF-A0236D1CDB5A

Q36602177-22EDAA18-15E8-4C4B-93B8-288F6F086211

Q36602177-2657CB01-D269-421E-B6EF-AD27F0A8D8DC

Q36602177-32C30863-2DB5-4AF2-A1AD-724D7079DB0F

Q36602177-3A6989F2-97AA-41E4-A6CE-121314631E76

Q36602177-4353C5F5-529B-488F-BEAA-F92F4246CA66

P304

Q36602177-B4B27A1D-CBB9-414A-B5DA-F696A6E5E1DF

P31

Q36602177-6AE47BC8-AD05-4B97-B9A6-E8DEEF90AC0C

P356

Q36602177-937AFDF3-1A89-451D-8C25-6342F70907F4

P433

Q36602177-7D2A0B21-DD0A-4845-8F2E-3B29596D421C

P478

Q36602177-402D3336-A00A-42A4-9031-C64359600FB7

P577

Q36602177-544B7890-850A-4F92-87E0-529656A25942

P5875

Q36602177-1913AE87-4F48-4514-AE86-9F2BE416E83F

P698

Q36602177-B267D2B9-753F-453E-9140-BB1662CF2B5E

P921

Q36602177-D9213A76-F5BD-4423-BE35-9D15B5C76E1A

P932

Q36602177-AF2755F8-FDD8-48FF-A3A7-8DE04C59819E

P356

P1433

EMBO Molecular Medicine

P1476

Sphingosine analogue drug FTY7 ...... A-RIPK1-dependent necroptosis.

@en

P2093

Amyn A Habib

http://www.w3.org/2001/XMLSchema#string

Angen Liu

http://www.w3.org/2001/XMLSchema#string

Archana Mukhopadhyay

http://www.w3.org/2001/XMLSchema#string

Besim Ogretmen

http://www.w3.org/2001/XMLSchema#string

Can E Senkal

http://www.w3.org/2001/XMLSchema#string

Danilo Perrotti

http://www.w3.org/2001/XMLSchema#string

Dzmitry Fedarovich

http://www.w3.org/2001/XMLSchema#string

Elizabeth Garrett-Mayer

http://www.w3.org/2001/XMLSchema#string

Jacek Bielawski

http://www.w3.org/2001/XMLSchema#string

Joshua Oaks

http://www.w3.org/2001/XMLSchema#string

P2860

Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule

NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-α feedforward signaling

Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase

The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways

Structural basis for specific lipid recognition by CERT responsible for nonvesicular trafficking of ceramide

Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1

Binding of the PX domain of p47(phox) to phosphatidylinositol 3,4-bisphosphate and phosphatidic acid is masked by an intramolecular interaction

The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A

Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation

Ripped to death

P304

105-121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/EMMM.201201283

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233770527

http://www.w3.org/2001/XMLSchema#string

P698

23180565

http://www.w3.org/2001/XMLSchema#string

P921

P932

3569657

http://www.w3.org/2001/XMLSchema#string